1. Introduction {#sec1}
===============

Immunoglobulin G4-related disease (IgG4-RD) is a relatively new multiorgan disease, characterized by an immune-mediated fibroinflammatory process, which can produce irreversible organ damage if untreated \[[@B1]--[@B3]\]. The clinical manifestations of this disease depend on the type and degree of organ involvement, making the diagnosis challenging for healthcare providers \[[@B4], [@B5]\].

Over the past few years, there has been increased understating of this condition, and the multiple disorders that were once described as isolated entities are now included under IgG4-RD spectrum \[[@B2], [@B3]\]. More importantly, there are now more therapeutic options available that can significantly change both outcome and prognosis; therefore, a correct diagnosis is even more crucial \[[@B6], [@B7]\].

We present an atypical presentation of IgG4-RD, with not only glandular and ophthalmic involvement but also thoracic paravertebral infiltration. In addition, to the best of our knowledge, this is the first reported case of IgG4-RD in two members of the same family.

2. Case Presentation {#sec2}
====================

A 50-year-old African American male with a past medical history of hypertension, gout, sleep apnea, and hypothyroidism was evaluated for abdominal pain, associated with unintentional 20-pound weight loss, nausea, and vomiting. He denied fever, chills, night sweats, headaches, dyspnea, skin rash, arthralgias, oral ulcers, Raynaud\'s phenomenon, or chest pain.

On physical exam, he was found to have bilateral parotid and submandibular gland enlargement and right eye proptosis. The patient disclosed that his brother has retroperitoneal fibrosis secondary to IgG4-RD. The initial abdominal computed tomography (CT) revealed a duodenal mass. Endoscopic retrograde cholangiopancreatography (ERCP) showed a mildly dilated common bile duct, not associated with mass or stricture. A biopsy of the intra- and infra-ampullary area demonstrated active chronic duodenitis without evidence of malignancy.

A CT of the thorax showed a confluence of elongated anterior and right paravertebral soft tissue from the midthoracic region to the diaphragmatic level, associated with mildly enlarged thoracic lymph nodes, borderline ascending aortic aneurysm, and scattered small lung nodules ([Figure 1](#fig1){ref-type="fig"}).

Complete blood count and biochemical profile were remarkable for chronic anemia and hypoalbuminemia, with normal renal and hepatic function. Monoclonal protein evaluation showed elevated IgG level of 5410 mg/dL (normal: 700--1600 mg/dL), and bone marrow biopsy demonstrated plasma cell dyscrasia (plasma cell count of 6%) with no evidence of lymphoproliferative disorder. Additional laboratory results revealed positive antinuclear antibody (ANA), low complement levels, elevated total IgG and IgG4 subclass, and elevated sedimentation rate ([Table 1](#tab1){ref-type="table"}). The QuantiFERON^®^-TB Gold test was negative.

He underwent excision of a submandibular gland, and the pathology revealed chronic sclerosing sialadenitis, with a large subset of inflammatory cells positively staining for IgG4 ([Figure 2](#fig2){ref-type="fig"}).

Subsequently, video-assisted thoracoscopy (VATS) was performed. During the procedure, a multilobar paraspinal mass near the diaphragm was noted, with pathology showing dense fibrosclerosis with increased lymphocytic infiltrates. Although staining for IgG and IgG4 was limited by the level of background staining and areas of crush artifact within the tissue, there was an increase of IgG4 plasma cells ([Figure 3](#fig3){ref-type="fig"}).

A follow-up chest CT revealed a prominent paravertebral mass. In view of this finding, the patient was started on prednisone 40 mg daily. While on prednisone, he significantly improved. A subsequent CT done 5 months later showed a decrease in the paraspinal mass ([Figure 1](#fig1){ref-type="fig"}). The serum IgG4 level also decreased significantly with prednisone treatment ([Table 2](#tab2){ref-type="table"}). Unfortunately, after prednisone was discontinued, the IgG4 level increased, and there was slight progression in thickness of the paravertebral soft tissue.

Prednisone was restarted, and rituximab therapy was planned.

3. Discussion {#sec3}
=============

IgG4-RD is a relatively new systemic fibroinflammatory disease. It is more common in male patients above age 50 \[[@B1], [@B2]\]. The pathophysiology is poorly understood, but genetic, infectious, and autoimmune factors may play a role \[[@B3]\]. The most common manifestations are type 1 autoimmune pancreatitis, sialadenitis, dacryoadenitis, tubulointerstitial nephritis, retroperitoneal fibrosis, and lymphadenopathy \[[@B2], [@B4], [@B6]\].

The diagnosis is based on clinic-pathologic correlation. Clinical manifestations depend on the type and degree of organ involvement. Solid organ involvement commonly presents as an inflammatory pseudotumor \[[@B8], [@B9]\]. Laboratory findings are nonspecific. High serum IgG4 level defined as IgG4 ≥ 135 mg/dL is present in most of the cases \[[@B3]\]. Acute reactive markers can be highly elevated or normal, and complement levels can be low.

The gold standard for diagnosis is biopsy, which also can differentiate this entity from other conditions such as lymphoma \[[@B1], [@B3]\]. The typical pathological findings are (1) diffuse lymphoplasmocytic infiltrates rich in IgG4 plasma cells (more than 10/high power field) and/or tissue IgG4/IgG ratio more than 40%, (2) storiform fibrosis, and (3) obliterative phlebitis.

Our patient presented with a paravertebral mass as a manifestation of IgG4-RD. There are only a few case reports that describe this atypical presentation \[[@B1], [@B4], [@B9], [@B10]\]. Watanabe et al. presented a unique familiar case report of type 1 autoimmune pancreatitis associated with IgG4-related sialadenitis and retroperitoneal fibrosis \[[@B11]\]. Similarly, our patient\'s brother has symptoms suggestive of IgG4-RD, and if true, this would represent another example of the possible genetic link in this illness.

Early recognition and treatment can prevent permanent organ damage since chronic inflammation leads to a tumefactive mass that can destroy the involved organ \[[@B1], [@B3]\]. There are no randomized controlled trials for IgG4-RD treatment. The International Consensus Guidance statement recommends initiation of treatment in all symptomatic patients, and glucocorticoids are the first-line agent for remission induction. However, patients can relapse after prednisone is tapered or discontinued. The use of steroid-sparing agents is controversial, and rituximab is an option for refractory cases \[[@B1], [@B5], [@B6]\]. The study conducted by Carruthers et al. showed 97% complete remission after two doses of rituximab \[[@B7]\], using serum IgG4 level as an important tool to assess treatment response and to predict possible relapse \[[@B12]\].

In conclusion, systemic involvement and possible permanent organ damage from IgG4-RD can present insidiously, so all physicians should be aware of this infrequent but important condition since early diagnosis and treatment may alter the prognosis of this multisystem disease. In addition, if there is a family history of IgG4-RD, this should not deter one from considering the diagnosis as our interesting case illustrates.
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![Paravertebral soft tissue mass (a) before and (b) after treatment with prednisone.](CRIRH2017-4716245.001){#fig1}

![The submandibular gland shows extensive lymphoplasmacytic infiltrate intermixed with prominent fibrosis.](CRIRH2017-4716245.002){#fig2}

![The paravertebral mass shows dense fibrosclerosis with increased lymphoplasmacytic infiltrates, and IgG4 plasma cells are slightly increased.](CRIRH2017-4716245.003){#fig3}

###### 

Baseline autoimmune workup.

  ---------------------------- ----------
  ANA                          1 : 640
  c-ANCA                       \<1 : 20
  p-ANCA                       \<1 : 20
  Rheumatoid factor (IU/mL)    \<15
  Smith antibody (units)       3
  RNP antibody (units)         4
  SSA/Ro antibody (units)      10
  SSB/La antibody (units)      4
  C3 (mg/dL)                   40
  C4 (mg/dL)                   6
  Sedimentation rate (mm/Hr)   72
  ---------------------------- ----------

###### 

Laboratory results before and after prednisone (prednisone was started on June 2015 and discontinued on November 2016).

                       April 2014   June 2015   December 2015   February 2016   April 2016   June 2016   September 2016   December 2016
  -------------------- ------------ ----------- --------------- --------------- ------------ ----------- ---------------- ---------------
  IgG4 (mg/dL)         4850         494         531             397             462          537         760              1210
  Sedimentation rate   28           72          26              11              ---          18          ---              41
  CRP                  \<0.3        \<0.3       \<0.3           \<0.3           0.1          \<0.1       ---              0.1
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